Did Trump's approval rating drop after the Iran strikes? Here's what the polls show
Several polls released following his decision to bomb multiple nuclear sites in Iran, however, offer initial glimpses into how the conflict could be affecting Americans' opinions of his job performance.
Four polls released in the last week showed the president with a 40% or 41% approval rating, several points below June averages that hovered around 45%.
On the flipside, one recent poll showed President Trump at a 51% approval rating. The poll numbers come amid a CNN/SSRS survey also released June 24 showing a majority of Americans disapprove of the president's strikes in Iran.
Here are the latest approval ratings released for Trump's administration:
The Economist
Most recent Trump approval rating, according to the latest from The Economist (June 30, 2025):
Favorable: 40%
Unfavorable: 55%
Not sure: 5%
The latest report shows that voters believe the top three most important issues Americans are facing are inflation/prices, jobs and the economy, followed by health care.
Silver Bulletin
Most recent Trump approval rating according to Pollster Nate Silver's 'Silver Bulletin' newsletter (June 30, 2025):
Favorable: 45%
Unfavorable: 52%
Civiqs
Most recent Trump approval rating, according to the latest Civiqs poll (June 28, 2025):
Favorable: 42%
Unfavorable: 54%
Neutral: 3%
Rasmussen
Most recent Trump approval rating, according to the latest Rasmussen poll (June 27, 2025):
Favorable: 51%
Unfavorable: 48%
The latest figures include 35% of U.S. voters who "strongly approve" of the job Trump is doing as president as well as 40% of voters who "strongly disapprove," according to the report.
Real Clear Politics
Most recent Trump approval rating, according to the latest Real Clear Politics poll (June 27, 2025):
Favorable: 47%
Unfavorable: 51%
New York Times
Most recent Trump approval rating, according to the latest New York Times poll (June 27, 2025):
Favorable: 44%
Unfavorable: 52%
Quinnipiac University
Most recent Trump approval rating, according to the latest Quinnipiac University poll (June 26, 2025):
Favorable: 41%
Unfavorable: 54%
Morning Consult
Most recent Trump approval rating, according to the latest Morning Consult poll (June 23, 2025):
Favorable: 45%
Unfavorable: 53%
Reuters/Ipsos
Most recent Trump approval rating, according to the latest Reuters/Ipsos poll (June 21-23, 2025):
Favorable: 41%
Unfavorable: 57%
Gallup
Most recent Trump approval rating, according to the latest Gallup poll (June 1-19, 2025):
Favorable: 40%
Unfavorable: 57%
No opinion: 3%
Navigator Research
Most recent Trump approval rating, specifically regarding the public's perception of President Trump, according to the latest Navigator Research poll (June 18, 2025):
Favorable: 42%
Unfavorable: 55%
According to the report, 57% of Americans disapprove of how Trump is handling the economy, compared to 41% who approve. Independents in particular overwhelmingly disapprove of Trump's handling of the presidency, with 28% in support and 63% not. According to the report, it is "the lowest it's been since his inauguration."
Cygnal
Most recent Trump approval rating, which has "barely budged since May," according to the latest Cygnal poll (June 10, 2025):
Favorable: 46%
Unfavorable: 51%
A president's approval rating reflects the percentage of Americans polled who approve of the president's performance. Anything can impact a president's rating, such as legislation passed, actions and elections. According to ABC News, an approval rating doesn't just represent how well the administration is faring for the general public but could factor into the outcome of an upcoming election or how much they accomplish while in office.
Presidential approval ratings were first conducted by the founder of the American Institute of Public Opinion, George Gallup, around 1935 to gauge public support for the president of the United States during their term. While Gallup has tracked presidential approval for 70 years, other organizations also conduct and release their own polls. Among them, Ipsos and Morning Consult.
A historical analysis by Gallup shows Trump's approval ratings in June of his first years in office − both as the 45th and 47th presidents − are lower than any other modern president at the same time in their administrations. The average is 52%, according to the report.
In the poll - conducted from June 2-19 - 40% approved of Trump's job performance. Here is how that compares to other presidents in June of their first year of their term, according to Gallup:
Joe Biden (June 2021) - 56% approve
Donald Trump (June 2017) - 38% approve
Barack Obama (June 2009) - 61% approve
George W. Bush (June 2001) - 54% approve
Bill Clinton (June 1993) - 41% approve
George H.W. Bush (June 1989) - 70% approve
Ronald Reagan (June 1981) - 59% approve
Jimmy Carter (June 1977) - 63% approve
Richard Nixon (June 1969) - 63% approve
John F. Kennedy (June 1961) - 73% approve
Contributing USA Today
This article originally appeared on Rockland/Westchester Journal News: Donald Trump approval ratings: What the polls show
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
West Pharma raises annual profit forecast on strong demand for its drug components
(Reuters) -Medical equipment maker West Pharmaceutical raised its annual profit forecast on Thursday, after topping second-quarter estimates on robust demand for its components used in GLP-1 weight-loss and diabetes drugs as well as a weaker dollar. The Pennsylvania-based firm's shares rose 16.8% to $264 premarket following the results. The company's drug components business, which makes up 47% of its total sales, saw a rise in demand amid sales growth in high-margin products. It also credited normalized customer ordering patterns for its quarterly performance. West Pharma's products are used by major pharmaceutical firms, including Eli Lilly and Novo Nordisk, in the administration of a wide range of therapies. The company supplies components such as stoppers, plungers and delivery systems that are critical to the safe packaging and administration of vaccines, biologics and other injectable medicines. West Pharma, which generates about half of its revenue from international markets, flagged a $20 million to $25 million hit to its earnings in April due to U.S. President Donald Trump's shifting trade policies. However, its second-quarter sales rose 9.2% to $766.5 million from a year ago, beating analysts' average estimate of $727.5 million, according to data compiled by LSEG. The company posted quarterly profit of $1.84 per share on an adjusted basis, above expectations of $1.51. West Pharma expects 2025 adjusted profit between $6.65 and $6.85 per share, up from the prior view of $6.15 to $6.35. The medical equipment maker also raised its annual sales forecast to a range of $3.04 billion to $3.06 billion, compared with an earlier projection of $2.95 billion to $2.98 billion.
Yahoo
a few seconds ago
- Yahoo
Nasdaq profit beats estimates as volatile markets lift trading volumes
(Reuters) -Nasdaq beat Wall Street estimates for second-quarter profit on Thursday, as volatile markets boosted trading volumes while first-half listings on its eponymous exchange hit their highest since 2021. U.S. markets were roiled during the quarter due to President Donald Trump's aggressive tariff announcements, renewed tensions in the Middle East and uncertainty over the Federal Reserve's monetary policy. The resulting volatility drove a spike in trading volumes, with Nasdaq recording a surge in U.S. equity options contracts, while U.S. cash equities volumes hit a record. The company's market services revenue from trading grew 21% to a quarterly record. Revenue from its financial technology unit, which includes anti-financial crime and capital markets infrastructure software, increased 10% to $464 million in the second quarter, while its index business revenue jumped 17% to $196 million. The company has expanded beyond trading and listings into financial technology and software to generate more predictable, recurring revenue that is less sensitive to market volatility. IPO MARKET RECOVERS IPO activity on the exchange rebounded in the first half of 2025, reaching its highest level since 2021, when listings had hit a global record. Several high-profile companies chose the exchange for their market debut, while mergers with blank-check firms and listing transfers from rival exchanges also contributed to Nasdaq's gains. Companies such as neo-bank Chime and AI infrastructure firm CoreWeave helped lift deal activity for Nasdaq, signaling a tentative return of investor appetite for new offerings after a years-long dry spell. In June, CEO Adena Friedman said Nasdaq was in active talks with companies looking to make stock market debuts, reflecting optimism for a broader recovery in the listings market. Nasdaq reported second-quarter revenue of $1.31 billion, up 13% from a year earlier. Profit came in at 85 cents per share in the three months ended June 30. Analysts on average had expected 81 cents, according to data compiled by LSEG.
Yahoo
a few seconds ago
- Yahoo
Algoma Steel seeking federal support amid ongoing concern over U.S. tariffs
SAULT STE. MARIE — Algoma Steel says it is seeking $500 million in federal support as the company faces continued uncertainty from U.S. tariffs on Canadian steel. The Sault Ste. Marie, Ont.-based steel producer says it applied for the funding under the Large Enterprise Tariff Loan program, announced by Ottawa in March to support companies affected by tariffs and countermeasures. The company says in a press release it remains concerned with the "significant impact" that U.S. tariffs are having on its operations and outlook. In June, U.S. President Donald Trump signed an executive order doubling his country's tariffs on steel and aluminum imports to 50 per cent. Algoma says it has enough resources on hand to manage its liquidity over the near term, but it is considering various options to achieve support and diversify its customer base, "given the ongoing uncertainty caused by the U.S. tariffs resulting in a structural imbalance in the Canadian market." That includes an evaluation of capital investments "that align with long-term domestic demand in sectors such as defence and construction, while reinforcing Canada's industrial resilience and low-carbon transformation." It says the amount of additional financing it could seek will partly depend on the duration and severity of the trade dispute "and the extent to which the Canadian steel market remains exposed to unfairly priced imports." This report by The Canadian Press was first published July 24, 2025. Companies in this story: (TSX:ASTL) The Canadian Press Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
